OnKure Therapeutics, Inc. (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.
The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors. OKI-179 is designed to achieve potent antitumor activity while minimizing the off-target toxicities associated with earlier HDAC inhibitors. In parallel, OnKure is developing OKI-272, a reversible Bruton’s tyrosine kinase (BTK) inhibitor targeting B-cell malignancies and autoimmune conditions, with ongoing preclinical and early clinical assessments.
Founded by a team experienced in drug discovery and clinical development, OnKure leverages integrated chemistry, biology, and translational science capabilities to move its pipeline forward. The company collaborates with specialized contract research organizations and academic centers to support its clinical programs and accelerate development timelines.
OnKure’s management team brings together industry veterans with extensive backgrounds in oncology drug development, clinical operations, and regulatory affairs. The company is committed to advancing its therapeutic candidates through clinical proof-of-concept and toward potential commercialization for patients with high unmet medical needs.
AI Generated. May Contain Errors.
